Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/177728
Full metadata record
DC FieldValueLanguage
dc.contributor.authorPascual, Tomás-
dc.contributor.authorOliveira, Mafalda-
dc.contributor.authorCiruelos, Eva-
dc.contributor.authorBellet Ezquerra, Meritxell-
dc.contributor.authorSaura, Cristina-
dc.contributor.authorGavilá, Joaquin-
dc.contributor.authorPernas, Sònia-
dc.contributor.authorMuñoz, Montserrat-
dc.contributor.authorVidal, Maria J.-
dc.contributor.authorMargelí Vila, Mireia-
dc.contributor.authorCejalvo Andújar, Juan Miguel-
dc.contributor.authorGonzález Farré, Blanca-
dc.contributor.authorEspinosa Bravo, Martin-
dc.contributor.authorCruz, Josefina-
dc.contributor.authorSalvador Bofill, Francisco Javier-
dc.contributor.authorGuerra, Juan Antonio-
dc.contributor.authorLuna Barrera, Ana María-
dc.contributor.authorArumi de Dios, Miriam-
dc.contributor.authorEsker, Stephen-
dc.contributor.authorFan, Pang-dian-
dc.contributor.authorMartínez Sáez, Olga-
dc.contributor.authorVillacampa, Guillermo-
dc.contributor.authorParé, Laia-
dc.contributor.authorFerrero Cafiero, Juan M.-
dc.contributor.authorVillagrasa, Patricia-
dc.contributor.authorPrat Aparicio, Aleix-
dc.date.accessioned2021-05-28T09:50:37Z-
dc.date.available2021-05-28T09:50:37Z-
dc.date.issued2021-04-23-
dc.identifier.urihttp://hdl.handle.net/2445/177728-
dc.description.abstractBackground: Preclinical data support a key role for the human epidermal growth factor receptor 3 (HER3) pathway in hormone receptor (HR)-positive breast cancer. Recently, new HER3 directed antibody drug conjugates have shown activity in breast cancer. Given the need to better understand the molecular biology, tumor microenvironment, and mechanisms of drug resistance in breast cancer, we designed this window-of-opportunity study with the HER3 directed antibody drug conjugate patritumab deruxtecan (HER3-DXd; U3-1402). Trial Design: Based on these data, a prospective, multicenter, single-arm, window-of-opportunity study was designed to evaluate the biological effect of patritumab deruxtecan in the treatment of naïve patients with HR-positive/HER2-negative early breast cancer whose primary tumors are ≥1 cm by ultrasound evaluation. Patients will be enrolled in four cohorts according to the mRNA-based ERBB3 expression by central assessment. The primary endpoint is a CelTIL score after one single dose. A translational research plan is also included to provide biological information and to evaluate secondary and exploratory objectives of the study.-
dc.format.extent9 p.-
dc.format.mimetypeapplication/pdf-
dc.language.isoeng-
dc.publisherFrontiers Media S. A.-
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.3389/fonc.2021.638482-
dc.relation.ispartofFrontiers in Oncology, 2021-
dc.relation.urihttps://doi.org/10.3389/fonc.2021.638482-
dc.rightscc by (c) Pascual et al., 2021-
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.subject.classificationCàncer de mama-
dc.subject.classificationReceptors d'hormones-
dc.subject.otherBreast cancer-
dc.subject.otherHormone receptors-
dc.titleSOLTI-1805 TOT-HER3 Study Concept: A Window-of-Opportunity Trial of Patritumab Deruxtecan, a HER3 Directed Antibody Drug Conjugate, in Patients With Early Breast Cancer-
dc.typeinfo:eu-repo/semantics/article-
dc.typeinfo:eu-repo/semantics/publishedVersion-
dc.date.updated2021-05-27T12:51:38Z-
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess-
dc.identifier.pmid33968735-
Appears in Collections:Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)
Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
Articles publicats en revistes (Medicina)

Files in This Item:
File Description SizeFormat 
fonc-11-638482.pdf2.38 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons